LLP-3

Name: LLP-3
Brand: TargetMol
SKU: T35542
Price: 200 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: LLP3, LLP 3) Copy Product Info

🥰Excellent

Synonyms: LLP3, LLP 3

Catalog No. T35542 Copy Product Info

Purity: 98.15%

🥰Excellent

LLP-3 is a class of Survivin inhibitor that interferes with the interaction of the Survivin-Ran protein complex in cancer cells and can be used in related studies of glioblastoma multiforme.

Cas No. 1453835-43-2

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$200	-	In Stock
5 mg	$419	-	In Stock
10 mg	$597	-	In Stock
25 mg	$948	-	In Stock
50 mg	$1,280	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:98.15%

Appearance:Solid

Color:Yellow

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	LLP-3 is a class of Survivin inhibitor that interferes with the interaction of the Survivin-Ran protein complex in cancer cells and can be used in related studies of glioblastoma multiforme.
In vitro	Methods: Cells were treated with LLP-3 (20 μM) for 24 h. Results: LLP-3 disrupted the binding of Survivin to the pro‑apoptotic protein Smac/DIABLO, without affecting the interaction of Survivin with other chromosomal passenger complex (CPC) proteins. Methods: U87 cells were treated with LLP-3 (20 μM) for 24 h. Results: LLP-3 reduced the interaction level between Survivin and Ran in U87 cells. Methods: Cells were treated with LLP-3 (20 μM) for 24 h. Results: LLP-3 arrested cells at the G0‑G1 phase, thereby inducing tumor cell death. Methods: HT1080 cells were treated with LLP-3 (20 μM) for 24 h. Results: LLP-3 triggered caspase‑dependent apoptosis in HT1080 cells. Methods: Tumor cells were treated with LLP-3 (0–100 μM) for 72 h. Results: LLP-3 decreased tumor cell viability through p53‑mediated inhibition[1].
In vivo	Methods: Mice bearing GBM sphere-derived tumors were intraperitoneally injected with LLP-3 (25 mg/kg) for 10 consecutive days. Results: LLP-3 prolonged the survival time of mice bearing GBM sphere-derived tumors[1].
Synonyms	LLP3, LLP 3

Chemical Properties

Molecular Weight	534.99
Formula	C₃₂H₂₃ClN₂O₄
Cas No.	1453835-43-2
Smiles	N#CC=1C(=O)NC(=CC1C=2C=C(OCC=3C=CC=CC3)C=C(OCC=4C=CC=CC4)C2)C=5C=C(Cl)C=CC5O

Storage & Solubility Information

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMF:PBS(pH7.2) (1:2): 0.3 mg/mL (0.56 mM), Sonication is recommended. DMF: 1 mg/mL (1.87 mM), Sonication is recommended. DMSO: 1 mg/mL (1.87 mM), Sonication is recommended. DMF: PBS(pH7.2) (1: 2): < 1 mg/mL (insoluble)

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.